Identifying And Validating Target for NAFLD Through in Silico Study

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, affecting a significant proportion of the population due to the rising prevalence of obesity and metabolic syndrome. NAFLD encompasses a spectrum of conditions, ranging from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), which can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The disease is closely linked to insulin resistance, dyslipidemia, and type 2 diabetes, making it a critical component of metabolic dysfunction. The pathogenesis of NAFLD involves complex interactions between genetic predisposition, dietary habits, lipid metabolism abnormalities, oxidative stress, and gut microbiota dysbiosis. While non-invasive diagnostic tools such as imaging modalities and serum biomarkers have improved early detection, challenges remain in accurately assessing disease severity and progression. Currently, lifestyle modifications, including weight loss, exercise, and dietary interventions, are the cornerstone of treatment. However, novel therapeutic targets focusing on metabolic regulation, inflammation control, and fibrosis inhibition are under investigation to provide effective pharmacological options. Given the significant impact of NAFLD on liver-related and cardiovascular morbidity, early detection and comprehensive management strategies are essential. Future research should prioritize personalized medicine approaches, improved biomarkers, and targeted therapies to prevent disease progression and reduce the global burden of NAFLD.